Shaveta Vinayak
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers 13
- PARP inhibition in cancer therapy 13
- Cancer Treatment and Pharmacology 6
- Cancer Research top 5%
- Breast Cancer Treatment Studies 9
- Cancer Genomics and Diagnostics 9
-
- Advanced Breast Cancer Therapies 10
-
- BRCA gene mutations in cancer 7
-
- Medical Imaging Techniques and Applications 6
- Co-authors
- Melinda L. TelliJames M. FordWilliam F. SimondsRobert W. CarlsonGerburg M. WulfPatrick M. DillonMonica MitaSara M. Tolaney
- Cited by
- OncologyCancer ResearchImmunology
- Journals
- Proceedings of the National Academy of Sciences (1 paper)Journal of Biological Chemistry (1 paper)Journal of Clinical Oncology (14 papers)
- Partner nations
- United StatesAustraliaUnited Kingdom
In The Last Decade
Shaveta Vinayak
42 papers receiving 1.2k citations
Hit Papers
Peers
Comparison fields: 5 of 77
- Oncology 790
- Cancer Research 351
- Immunology 193
- Pulmonary and Respiratory Medicine 239
- Molecular Biology 429
Countries citing papers authored by Shaveta Vinayak
This map shows the geographic impact of Shaveta Vinayak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shaveta Vinayak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shaveta Vinayak more than expected).
Fields of papers citing papers by Shaveta Vinayak
This network shows the impact of papers produced by Shaveta Vinayak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shaveta Vinayak. The network helps show where Shaveta Vinayak may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Shaveta Vinayak, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 5 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 1 | |
| 4 | 2024 | 2 | |
| 5 | 2024 | 8 | |
| 6 | 2023 | 1 | |
| 7 | 2023 | 60 | |
| 8 | 2022 | 10 | |
| 9 | 2020 | 40 | |
| 10 | Extending Adjuvant Endocrine Therapy in Breast Cancer: Who, What, Why? | 2019 | 5 |
| 11 | 2019 | 23 | |
| 12 | 2017 | 55 | |
| 13 | 2017 | 78 | |
| 14 | 2017 | 14 | |
| 15 | 2016 | 9 | |
| 16 | 2016 | 91 | |
| 17 | 2014 | 22 | |
| 18 | mTOR inhibitors in the treatment of breast cancer. | 2013 | 40 |
| 19 | 2009 | 13 | |
| 20 | 2000 | 91 |
About Shaveta Vinayak
Shaveta Vinayak is a scholar working on Cancer Research, Oncology and Radiology, Nuclear Medicine and Imaging, having authored 45 papers that have together received 1.2k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (13 papers), PARP inhibition in cancer therapy (13 papers), Advanced Breast Cancer Therapies (10 papers), Breast Cancer Treatment Studies (9 papers), Cancer Genomics and Diagnostics (9 papers), BRCA gene mutations in cancer (7 papers), Medical Imaging Techniques and Applications (6 papers) and Cancer Treatment and Pharmacology (6 papers). The work is most often cited by research in Oncology (790 citations), Cancer Research (351 citations) and Immunology (193 citations). Shaveta Vinayak has collaborated with scholars based in United States, Australia and United Kingdom. Frequent co-authors include Melinda L. Telli, James M. Ford, William F. Simonds, Robert W. Carlson, Gerburg M. Wulf, Patrick M. Dillon, Monica Mita, Sara M. Tolaney, Corrine Zarwan and Antoinette R. Tan. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.